AbCellera Biologics Inc. Common Shares
Exchange: NASDAQ
Symbol: ABCL
SEC CIK: 0001703057
Phone: (604) 559-9005
2215 YUKON STREET
VANCOUVER A1 V5Y 0A1
CEO:
|
Price when page updated: 4.755 Date: 2023-11-30
Company Website:
www.abcellera.com
|
_Description: AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development.
IPO YEAR:
2020
|
Sector:
|
Industry:
|
ADRTSO:
|
MarketCap:
1375887148.00
|
Beta:
0.860895496089908
|
52 Week High:
55.22
|
52 Week Low:
12.2
|
52 Week Change:
-0.6480433757661481
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
281581275
|
Dividend Rate:
0
|
Dividend Yield:
N/A
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
7 Nov 2022
|
Float:
0
|
return on Equity:
18.20%
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
$286.523M
|
ttmEPS:
0
|
Revenue:
$507.337M
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
47.50%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
20.40%
|
Return on Assets:
14.10%
|
Return on Capital:
|
Profit Margin:
39.50%
|
Price to Sales:
6.46
|
Price To Book:
2.50
|
Short Ratio:
7.08
|
PE Ratio:
0
|
Employees:
206
|
1Y Guesstimate
22.661:2.0:6
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__AbCellera Biologics Inc. Common Shares [ ABCL ].
__Note: Some Links might not have information for the company.
|
|
